SpA, the Italy-based active pharmaceutical
ingredients (API) contract development and manufacturing organisation (CDMO) and generics supplier, has acquired Ricerca Biosciences’ chemical division of the contract research (CRO) and CDMO
based in Concord, Ohio (USA). This acquisition strengthens the service offering of Olon
for the pharmaceutical
and biotech industry, and to benefits the Ricerca Biosciences customer base by providing large scale manufacturing capabilities in Europe.
“By acquiring a research and manufacturing base in the US, Olon
will have the opportunity to accelerate growth by adding new CDMO
projects and to develop new Generic products for the American market,” commented Paolo Tubertini, CEO of Olon.
Luca Mantovani, Olon
managing board member, added, "We are delighted to add Ricerca Biosciences to Olon
Group, as this strategic step will broaden our contract research and manufacturing services for all our global customers.”
Ricerca Biosciences is the US-based CRO
supporting the development and manufacture of APIs and performance materials in support clinical supply, market development and commercial distribution.